Novel proteins

Abstract

The invention relates generally to mutant CD200 proteins which bind with greater affinity to the CD200 receptor than wild-type CD200, in particular the invention relates to a mutated CD200 protein comprising specific mutations at amino acid residue position 130 and/or 131. This invention also relates to a fusion protein comprising the protein as defined herein fused to a non-CD200 protein portion directly or via an optional linker portion, a pharmaceutical composition comprising the protein as defined herein and uses thereof.

Dependencies are inferred from the claim text.